SCHEMBL13627899

SCHEMBL13627899

O=C1/C(=N\O)c2ccccc2N1Cc1ccccc1[N+](=O)[O-]

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.56
CA12 O43570 1/20 0.48
CA2 P00918 1/20 0.48
CA9 Q16790 1/20 0.48
ALDH1A1 P00352 4/20 0.47
HTT P42858 2/20 0.47
TYR P14679 1/20 0.46
GSK3B P49841 8/20 0.44
GAA P10253 1/20 0.44
CASP1 P29466 1/20 0.43
CASP3 P42574 1/20 0.43
CASP7 P55210 1/20 0.43
CASP6 P55212 1/20 0.43
HPGD P15428 1/20 0.42
GRM5 P41594 1/20 0.41
LRRK2 Q5S007 1/20 0.41
MAPT P10636 1/20 0.41
PKM P14618 1/20 0.41
TSHR P16473 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13627935 0.86 ACHE (0.55) ACHECA12CA2CA9ALDH1A1
SCHEMBL13627909 0.86 ACHE (0.74) ACHECA12CA2CA9ALDH1A1
SCHEMBL13627925 0.86 ACHE (0.74) ACHECA12CA2CA9ALDH1A1
SCHEMBL13627949 0.86 ACHE (0.55) ACHECA12CA2CA9ALDH1A1
SCHEMBL18954615 0.83 ACHE (0.73) ACHECA12CA2CA9ALDH1A1
SCHEMBL13627895 0.80 MAPT (0.58) CA12CA2CA9ALDH1A1HTT
SCHEMBL13627898 0.79 ALDH1A1 (0.50) CA12CA2CA9ALDH1A1LRRK2
SCHEMBL4047966 0.78 TYR (0.67) ACHECA12CA2CA9ALDH1A1
SCHEMBL13627951 0.77 ALDH1A1 (0.72) CA12CA2CA9ALDH1A1HTT
SCHEMBL13627952 0.76 ALDH1A1 (0.41) CA12CA2CA9ALDH1A1LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 ACHE 4079/4885CA12 4791/4885CA2 3142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.